N-Acetyl Cysteine · Acetylcysteine
600 mg · vegan · gluten-free · 60 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
N-acetylcysteine (NAC) is a mucolytic and antioxidant precursor to glutathione. At high doses (1200–1800 mg/day), it reduces COPD exacerbation frequency and thins bronchial mucus by breaking disulfide bonds. It is one of the few respiratory supplements with meta-analysis support, though effect sizes are modest.
NAC donates cysteine for glutathione synthesis, reducing oxidative stress in inflamed airways. Its free sulfhydryl group cleaves disulfide bonds in mucus glycoproteins, reducing viscosity and improving expectoration. The antioxidant effect requires higher doses (≥1200 mg/day) than standard 600 mg mucolytic dosing.
Adults with COPD, chronic bronchitis, or recurrent respiratory infections seeking exacerbation prevention. Not a substitute for bronchodilators, inhaled corticosteroids, or smoking cessation.
Avoid if you have asthma (may trigger bronchospasm in rare cases). Use caution with anticoagulants. May cause nausea, diarrhea, or headache at high doses. Discontinue if rash or breathing difficulty occurs.
Pick a depth — minimum to maximal coverage
No full stack configured.
Click individual supplement pills above to buy each on Amazon India.
✓ Split doses to maintain steady mucolytic and antioxidant effect throughout the day
✓ Split doses to maintain steady mucolytic and antioxidant effect throughout the day
✓ Take with substantial meals to reduce nausea and improve tolerability at high doses
NAC donates cysteine for glutathione synthesis, reducing oxidative stress in inflamed airways.
Each bar = one cited trial. Effect varies by methodology, dose, and population.
Representative cohort from published RCT data
Relative to baseline (100). Data from published clinical literature.
20 studies, meta-analysis
→ NAC significantly reduced exacerbations in COPD (IRR=0.76) and chronic bronchitis (IRR=0.81). CB/pre-COPD patients were 3.47× more likely to experience symptom/QoL improvement.
29 RCTs, meta-analysis
→ Mucolytics including NAC reduced acute exacerbations (RR 0.76) and disability days (RR 0.65). No significant effect on lung function parameters.
12 RCTs, 2691 patients
→ High-dose (RR=0.90) and low-dose (RR=0.83) NAC reduced COPD exacerbation prevalence. Long-term (≥6 months) therapy was required for benefit. No effect on FEV1 or FVC.
B · Multiple meta-analyses (2015, 2017, 2024) consistently show modest exacerbation reduction. Effect sizes are small-to-moderate. No impact on lung function. High-dose (≥1200 mg) and long-term (≥6 months) use required.
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: Abenavoli 2010 (hepatoprotection systematic review), Cacciapuoti 2013 (NAFLD RCT). richResearch section contains study filters.
How to use NAC (Respiratory Dose) specifically for Thick mucus — the right dose, timing, blood markers to track, and how to know if it is working.
A clinical evidence review of NAC (Respiratory Dose) — RCT data, effect sizes, evidence grade, and what the numbers mean for your specific situation.
Everything you need to know about NAC (Respiratory Dose) — mechanism, dose, safety, buying guide for India, and what the research actually says.
SacredBod's longer take on NAC (Respiratory Dose) — context the structured blocks above don't capture.
N-acetylcysteine (NAC) is a mucolytic and antioxidant precursor to glutathione. At high doses (1200–1800 mg/day), it reduces COPD exacerbation frequency and thins bronchial mucus by breaking disulfide bonds. It is one of the few respiratory supplements with meta-analysis support, though effect sizes are modest.
NAC donates cysteine for glutathione synthesis, reducing oxidative stress in inflamed airways. Its free sulfhydryl group cleaves disulfide bonds in mucus glycoproteins, reducing viscosity and improving expectoration. The antioxidant effect requires higher doses (≥1200 mg/day) than standard 600 mg mucolytic dosing.
Who benefits most
Adults with COPD, chronic bronchitis, or recurrent respiratory infections seeking exacerbation prevention. Not a substitute for bronchodilators, inhaled corticosteroids, or smoking cessation.
Dosage and form
600 mg is the typical effective range. Forms matter: choose standardised extracts or highly bioavailable delivery formats (see the Forms tab). Take as directed.
Side effects and cautions
Sulfur burps. Rare GI upset. Avoid if you: Avoid if you have asthma (may trigger bronchospasm in rare cases). Use caution with anticoagulants. May cause nausea, diarrhea, or headache at high doses. Discontinue if rash or breathing difficulty occurs..
The evidence
Human clinical trials and mechanistic research support the use of NAC (Respiratory Dose) for its primary indication. See the Research tab for full citations and study summaries.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
